Research Comparison
Adipotide (Prohibitin-TP01) vs Retatrutide (LY3437943)
A side-by-side research comparison of Adipotide (Prohibitin-TP01) and Retatrutide (LY3437943) drawn from Cobalt Peptides' peptide database records.
Adipotide (Prohibitin-TP01)
Adipotide (Prohibitin-TP01) is a chimeric peptidomimetic combining a targeting sequence (CKGGRAKDC) that binds prohibitin and annexin A2 on adipose endothelial cells with a pro-apoptotic mitochondrial-disrupting motif, D-(KLAKLAK)2. It was investigated in preclinical models of adiposity. Its development was HALTED following early clinical investigation because of renal safety findings — reversible proximal tubule toxicity observed in primate studies. It is not an approved medicine and is supplied strictly as a research compound for laboratory use.
Retatrutide (LY3437943)
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist with activity at the GLP-1, GIP and glucagon receptors. Its design combines incretin-axis signalling through GLP-1 and GIP with glucagon receptor activity, a combination studied for its effects on energy balance in published metabolic research. Retatrutide is not an approved medicine in the United Kingdom or elsewhere and remains in clinical development by its originator. Supplied strictly as a research compound for laboratory use.